Who are Intravenous topotecan/cisplatin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-topotecan-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intravenous topotecan/cisplatin — Competitive Intelligence Brief

Intravenous topotecan/cisplatin (Intravenous topotecan/cisplatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy (topoisomerase I inhibitor + platinum alkylating agent). Area: Oncology.

phase 3 Combination chemotherapy (topoisomerase I inhibitor + platinum alkylating agent) Topoisomerase I; DNA (cisplatin cross-linking) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous topotecan/cisplatin (Intravenous topotecan/cisplatin) — GlaxoSmithKline. This combination uses topotecan to inhibit topoisomerase I and cisplatin to cross-link DNA, together inducing cancer cell death through multiple mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous topotecan/cisplatin TARGET	Intravenous topotecan/cisplatin	GlaxoSmithKline	phase 3	Combination chemotherapy (topoisomerase I inhibitor + platinum alkylating agent)	Topoisomerase I; DNA (cisplatin cross-linking)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy (topoisomerase I inhibitor + platinum alkylating agent) class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous topotecan/cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-topotecan-cisplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab